Relationship Between Calcium Channel Blockers Therapy and Cognitive Function Improvement in Cognitive Decline Patients with Cerebrovascular Disease

Overview

Journal High Blood Press Cardiovasc Prev

Specialty Cardiology & Vascular Diseases

Date 2022 Sep 27

PMID 36166186

Authors

Ho Tae Jeong

Hyun-Ho Sung

Jun Hong Lee

Kwang-Yeol Park

Young Chul Youn

Affiliations

Soon will be listed here.

Abstract

Introduction: Amlodipine belongs to a class of calcium channel blockers that relax blood vessels to allow easier flow of blood. Higher blood pressure (BP) is associated with cerebrovascular disease and is an important contributor to cognitive decline and dementia.

Aim: This study aimed to evaluate the effect of 24 weeks of S-amlodipine besylate therapy on cognitive function in patients with hypertension and cerebrovascular disease.

Methods: The data were obtained from a study of post-market surveillance of S-amlodipine besylate.

Results: A total of 545 subjects (mean age 67 ± 9.68 years) with hypertension and ischemic cerebrovascular disease were enrolled. Patients with a baseline Mini-Mental State Examination (MMSE) score above 26 were assigned to the cognitive normal (CN) (n = 294) group, and those with MMSE score less than 26 were in the cognitive decline (CD) (n = 251) group. After 24 weeks of treatment with S-amlodipine besylate 5 mg, MMSE and Global Deterioration Scale (GDS) were evaluated again. Changes in MMSE were compared in the target BP reached (TBPR) and non-reached (NTBPR) groups and for CN and CD groups. Treatment with 5 mg of S-amlodipine besylate for 24 weeks improved MMSE and GDS scores (p < 0.001). The CD group showed improvement in MMSE score regardless of whether target BP was obtained (TBPR: p < 0.001, NTBPR: p < 0.01). However, the CN classification was not significant for either TBPR or NTBPR groups.

Conclusions: S-amlodipine besylate improved cognition of the CD group with hypertension and cerebrovascular disease regardless of obtaining target BP.

References

Rigaud A, Seux M, Staessen J, Birkenhager W, Forette F . Cerebral complications of hypertension. J Hum Hypertens. 2000; 14(10-11):605-16. DOI: 10.1038/sj.jhh.1001118. View

Birkenhager W, Forette F, Seux M, Wang J, Staessen J . Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med. 2001; 161(2):152-6. DOI: 10.1001/archinte.161.2.152. View

Kennelly S, Lawlor B, Kenny R . Blood pressure and dementia - a comprehensive review. Ther Adv Neurol Disord. 2010; 2(4):241-60. PMC: 3002634. DOI: 10.1177/1756285609103483. View

Elias M, Wolf P, DAgostino R, Cobb J, White L . Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993; 138(6):353-64. DOI: 10.1093/oxfordjournals.aje.a116868. View

Kilander L, Nyman H, Boberg M, Hansson L, Lithell H . Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998; 31(3):780-6. DOI: 10.1161/01.hyp.31.3.780. View

Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A . Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999; 53(9):1948-52. DOI: 10.1212/wnl.53.9.1948. View

Murray M, Lane K, Gao S, Evans R, Unverzagt F, Hall K . Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med. 2002; 162(18):2090-6. DOI: 10.1001/archinte.162.18.2090. View

Tzourio C . Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin Neurosci. 2007; 9(1):61-70. PMC: 3181842. View

Liu F, Qiu M, Zhai S . Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2014; 71(1):1-29. PMC: 3967363. DOI: 10.1016/j.curtheres.2010.02.005. View

10.

Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T . Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000; 175(2):124-34. DOI: 10.1016/s0022-510x(00)00300-2. View

11.

Han C, Jo S, Jo I, Kim E, Park M, Kang Y . An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: demographic influence and population-based norms (the AGE study). Arch Gerontol Geriatr. 2007; 47(3):302-10. DOI: 10.1016/j.archger.2007.08.012. View

12.

Hajjar I, Goldstein F, Martin G, Quyyumi A . Roles of Arterial Stiffness and Blood Pressure in Hypertension-Associated Cognitive Decline in Healthy Adults. Hypertension. 2015; 67(1):171-5. PMC: 4715367. DOI: 10.1161/HYPERTENSIONAHA.115.06277. View

13.

Forette F, Seux M, Staessen J, Thijs L, Babarskiene M, Babeanu S . The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162(18):2046-52. DOI: 10.1001/archinte.162.18.2046. View

14.

Langley M, Sorkin E . Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989; 37(5):669-99. DOI: 10.2165/00003495-198937050-00004. View

15.

Hussain S, Singh A, Rahman S, Habib A, Najmi A . Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies. Neurosci Lett. 2018; 671:120-127. DOI: 10.1016/j.neulet.2018.02.027. View

16.

Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C . Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7(8):683-9. DOI: 10.1016/S1474-4422(08)70143-1. View

17.

Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B . Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324(7339):699-702. PMC: 99052. DOI: 10.1136/bmj.324.7339.699. View

18.

Vermeer S, Prins N, den Heijer T, Hofman A, Koudstaal P, Breteler M . Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003; 348(13):1215-22. DOI: 10.1056/NEJMoa022066. View

19.

Schneider J, Arvanitakis Z, Leurgans S, Bennett D . The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009; 66(2):200-8. PMC: 2812870. DOI: 10.1002/ana.21706. View